Wednesday, December 13, 2006 7:30:00 AM PDT | VentureDeal Staff
NC -- Asklepios BioPharmaceuticals has landed a
$2.5 million grant from the Muscular Dystrophy Association to continue clinical
human trials of its gene therapy for Duchenne muscular dystrophy.
The grant is the largest ever by the Muscular Dystrophy Association and will be
matched by the company. The purpose of the trials is to deliver the
therapy into multiple muscles in animals, since it has proven to be safe in
single muscle human trials.
The privately-held company was originally spun out of the University
of North Carolina at Chapel
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
Founded in 2006, VentureDeal is a database that provides the latest information about venture capital firms, venture-backed technology companies and transactions throughout North America.
Learn More »
© VentureDeal, Inc., Menlo Park, CA. All Rights Reserved.